Trial Profile
A Phase I/II Open-Label Multicenter Study to Evaluate the Safety and Efficacy of AK-01 as Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs AK 01 (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; HER2 negative breast cancer; Leiomyosarcoma; Non-small cell lung cancer; Periampullary cancer; Prostate cancer; Sarcoma; Solid tumours; Thymoma; Triple negative breast cancer; Uveal melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors AurKa Pharma; Eli Lilly and Company
- 22 Jan 2021 Status has been changed to discontinued, according to results published in the Investigational New Drugs.
- 22 Jan 2021 Results published in the Investigational New Drugs
- 03 Apr 2019 Results presented at the 110th Annual Meeting of the American Association for Cancer Research